Trial Profile
A prospective, open-label clinical trial, to evaluate the efficacy of intravitreal Aflibercept for the treatment of previously treated exudative age-related macular degeneration
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Choroidal neovascularisation; Wet age-related macular degeneration
- Focus Therapeutic Use
- 28 Aug 2017 New trial record